Axsome Therapeutics, Inc.
AXSM · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 50.04M | 44.84M | -179.80M | -187.13M | -4.60 |
| 2023 FY | 270.60M | 244.54M | -231.83M | -239.24M | -5.27 |
| 2024 FY | 385.69M | 352.39M | -280.56M | -287.22M | -5.99 |
| 2025 FY | 638.50M | 591.02M | -169.24M | -183.17M | -3.68 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 331.48M | 221.92M | 200.84M | 94.68M | 109.56M |
| 2023 FY | 588.24M | 397.26M | 386.19M | 186.37M | 190.98M |
| 2024 FY | 568.50M | 511.48M | 315.35M | 192.96M | 57.02M |
| 2025 FY | 689.81M | 601.51M | 322.93M | 241.30M | 88.30M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -116.51M | -702.00K | -117.21M | — | 114.37M |
| 2023 FY | -145.08M | -582.00K | -145.66M | — | 185.35M |
| 2024 FY | -128.41M | -270.00K | -128.68M | — | -70.84M |
| 2025 FY | -93.41M | -480.00K | -93.89M | — | 7.58M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 3.14B | 3.03B | — | — | — |
| 2023 FY | 3.62B | 3.42B | — | — | — |
| 2024 FY | 4.05B | 3.93B | — | — | — |
| 2025 FY | 9.09B | 9.00B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 150.04M | 136.59M | -36.71M | -47.97M | -0.97 |
| 2025 Q3 | 170.99M | 159.08M | -46.11M | -47.23M | -0.94 |
| 2025 Q4 | 196.00M | 183.67M | -29.43M | -28.56M | -0.56 |
| 2026 Q1 | 191.20M | 176.48M | -63.36M | -64.54M | -1.26 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 639.79M | 566.71M | 303.02M | 217.31M | 73.08M |
| 2025 Q3 | 669.25M | 595.52M | 325.27M | 218.60M | 73.73M |
| 2025 Q4 | 689.81M | 601.51M | 322.93M | 241.30M | 88.30M |
| 2026 Q1 | 713.61M | 659.02M | 305.11M | 219.90M | 54.59M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -32.42M | -13.00K | -32.44M | — | 2.11M |
| 2025 Q3 | 1.05M | -58.00K | 988.00K | — | 22.26M |
| 2025 Q4 | -18.65M | -71.00K | -18.72M | — | -2.34M |
| 2026 Q1 | -20.70M | -121.00K | -20.82M | — | -17.83M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 5.16B | 5.08B | — | — | — |
| 2025 Q3 | 6.08B | 5.97B | — | — | — |
| 2025 Q4 | 9.25B | 9.17B | — | — | — |
| 2026 Q1 | 8.65B | 8.57B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |